Sight Sciences Inc

Glaukos shares have surged 67.9% year to date, significantly outperforming its industry's 8.4% decline and the S&P 500's 12% return, driven by accelerating operating momentum from the commercial ramp of iDose TR and the early launch of Epioxa. Second-quarter revenues jumped 49.5% to $185.6 million, prompting management to raise 2026 revenue guidance by $60-$65 million to $680-$700 million. U.S. glaucoma revenues increased 64% to $118.5 million, with iDose TR sales reaching approximately $74 million, up 37% sequentially, while the Corneal Health franchise grew 48% to $30.4 million, including roughly $11 million from Epioxa. The company is expanding internationally, with second-quarter international revenues up 17% to $36.6 million, and is advancing a diversified pipeline across five novel therapeutic platforms and 13 publicly disclosed programs. Key risks include reimbursement execution for iDose TR, early-stage Epioxa commercialization, and competitive pressures from Alcon, Sight Sciences, and AbbVie.

The fair value estimate for Sight Sciences has been reduced from US$9.35 to US$8.40, reflecting more cautious assumptions on growth and profitability. Revenue growth expectations were lowered from 12.96% to 10.68%, while the net profit margin forecast declined from 12.90% to 11.46%. The future P/E multiple increased from 47.39x to 51.65x, and the discount rate was adjusted from 7.92% to 7.60%. UBS resumed coverage with a Buy rating but cut its price target from US$11 to US$7, while Citi raised its target twice in 2026, first to US$5.15 and then to US$6, maintaining a Neutral rating. Analysts noted generally solid conditions in medical technology and eyecare, though refractive procedures remain challenged, potentially limiting valuation upside.